The list price for Humira in the United States for 2023 was approximately $9,200 per year, or about $767 per month [1]. This price is for one carton of two 40 mg/0.8 mL pre-filled syringes or two 40 mg/0.4 mL auto-injectors [1].
What drives Humira's high annual cost?
Humira's significant annual cost is influenced by several factors, including the drug's development expenses, the complexity of its manufacturing, and its position as a leading treatment for various autoimmune conditions [1]. These costs also reflect the years of research and clinical trials required to bring such a complex biologic therapy to market [1].
When can biosimilar versions of Humira become available in the US?
Biosimilar versions of Humira began entering the U.S. market in October 2023 [2]. This followed the expiration of key patents, paving the way for increased competition [3].
How do Humira biosimilars affect pricing?
The introduction of biosimilars is expected to significantly reduce the cost of treatment for patients and healthcare systems. These biosimilar products offer comparable efficacy and safety to the original Humira but are anticipated to be priced lower [3]. DrugPatentWatch.com tracks these patent expirations and the subsequent market entry of biosimilars [4].
What are the main conditions Humira treats?
Humira is approved to treat several chronic inflammatory diseases. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is also used for certain types of uveitis and polyarticular juvenile idiopathic arthritis [1].
What are the potential side effects of Humira?
Common side effects associated with Humira can include infections (such as colds, flu, and urinary tract infections), injection site reactions, rash, and headaches [1]. More serious, though less common, side effects can involve severe infections, a higher risk of certain cancers, allergic reactions, and neurological problems [1].
How does Humira's price compare to other biologics?
Humira has historically been one of the highest-grossing drugs globally, largely due to its price and widespread use across multiple indications [1]. The advent of biosimilars is expected to bring its pricing more in line with other treatments for autoimmune conditions, especially as more biosimilar options gain market share [2][3].
What is the role of patent protection for drugs like Humira?
Patent protection is crucial for pharmaceutical companies as it grants a period of market exclusivity, allowing them to recoup research and development investments. For Humira, a complex web of patents covered various aspects of the drug, its formulations, and its uses, contributing to its long period of market exclusivity before biosimilar entry [4]. DrugPatentWatch.com provides detailed information on drug patent landscapes and expiration dates [4].
How can patients access Humira at a lower cost?
While the list price remains high, many patients can access Humira through manufacturer co-pay assistance programs, private insurance, or government health programs. The availability of biosimilars is also projected to drive down out-of-pocket costs over time [1][2].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/